Blueprint Investment Partners LLC Gilead Sciences, Inc. Transaction History

Blueprint Investment Partners LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $356,971 - $404,814	4,872 New	4,872 $394,000
Q2 2023 Aug 15, 2023	SELL	$76.01 - $86.7 $183,260 - $209,033	-2,411 Reduced 29.14%	5,864 $451,000
Q1 2023 May 12, 2023	SELL	$77.31 - $88.08 $241,980 - $275,690	-3,130 Reduced 27.44%	8,275 $686,000
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $481,671 - $691,513	7,729 Added 210.26%	11,405 $979,000
Q3 2022 Nov 09, 2022	SELL	$59.54 - $68.01 $67,696 - $77,327	-1,137 Reduced 23.62%	3,676 $227,000
Q2 2022 Aug 09, 2022	BUY	$57.72 - $65.01 $277,806 - $312,893	4,813 New	4,813 $297,000
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $469,325 - $588,115	-8,103 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$64.88 - $73.64 $173,294 - $196,692	2,671 Added 49.17%	8,103 $588,000
Q3 2021 Nov 04, 2021	BUY	$67.69 - $73.03 $367,692 - $396,698	5,432 New	5,432 $379,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Blueprint Investment Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Blueprint Investment Partners LLC with notifications on news.